US FDA Classifies Recall Of Philips’ Respiratory Devices As Most Serious

Maryland (Reuters) The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of Dutch medical devices maker Philips’ respiratory machines as most serious, saying their use could lead to injuries or death.

The U.S. health regulator said the silicon foam used in some reworked ventilator models may separate from plastic backing due to adhesive failure and can reduce the air flow as well as cause debris contamination.

The company’s ventilators provide breathing assistance to both pediatric and adult patients.

The recall follows Philips’ move to call back millions of breathing devices and ventilators in June 2021 due to the potential of a foam part degrading and becoming toxic, possibly causing cancer.

Its subsidiary, Philips Respironics, had in December also recalled about 13,811 ventilators which were distributed between March 1, 2022 and Sept. 6, 2022.

Philips did not immediately respond to a Reuters request for comment on the impact from the recall.

There were 82 complaints till Jan. 4 and no reports of death or long-term injuries associated with the use of the product, the U.S. FDA said.

  • Related Posts

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    US market to dent India pharma earnings even as domestic growth remains firm

    US market to dent India pharma earnings even as domestic growth remains firm

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg